Effects of enoxaparin in chemotherapy patients with stage phase III B non-small cell lung cancer

Abstract

Objective To evaluate the effect of low molecular heparin in chemotherapy of phase ⅢB non-small cell lung cancer.Methods 62 patients with Ⅲ B non-small cell lung cancer were administrated the chemotherapy of docetaxel combined with cisplain (docetaxel 75 mg/m2,combined with cisplain 75 mg/m2 given in one hour and two hours respectively,with the total of 4-6 circles).Patients were randomly assigned to receive low molecular heparin therapy(low molecular weight heparin sodium gel 100 IU/kg given subcutaneously for five days on every circle) or not.The overall survival,progression-free survival,frequency of granulocytopenia,functional status score,hemorrhage event,and level of D-dimer between the two groups were compared.Results The one-year or two-year overall survival rate in treatment group with low molecular heparin was higher than that in treatment group without low molecular heparin treament (64.52％ vs 38.71％,22.58％ vs 9.68％,P =0.048).The oneyear or two-year progression-free survival was similar in treatment group with low molecular heparin and treatment group without low molecular heparin (32.26％ vs 29.03％,12.90％ vs 9.68％,P =0.723).The performance status score,granulocytopenia,and hemorrhage event were similar between the two groups.The level of D-dimer in treatment group with low molecular heparin was lower than that in treatment group without low molecular heparin [(145.97±58.66) μg/L vs (190.39±55.81) μg/L,P =0.003].Conclusions Low molecular heparin therapy may help extend the overall survival of phase Ⅲ B non-small cell lung cancer with the therapy of docataxel and cisplain and alleviate hypercoagulable states of blood. Key words: Non-small cell lung cancer; Chemotherapy; Low molecular weight heparin